MARKET

RPHM

RPHM

Reneo Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.20
+0.40
+3.13%
Closed 16:00 04/22 EDT
OPEN
12.77
PREV CLOSE
12.80
HIGH
13.46
LOW
12.53
VOLUME
143.38K
TURNOVER
--
52 WEEK HIGH
17.18
52 WEEK LOW
11.63
MARKET CAP
319.58M
P/E (TTM)
-6.1547
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 04/14 11:51
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 04/13 12:16
DJ Reneo Pharmaceuticals Shares Move Lower in Debut After IPO >RPHM
Dow Jones · 04/09 17:21
Biotech Reneo Pharmaceuticals trades today after pricing IPO at $15
Reneo Pharmaceuticals (RPHM) has priced its initial public offering of 6.25M shares at $15.00 per share, for total gross proceeds of ~$93.8M.Trading kicksoff today on Nasdaq.Underwriters' overallotment is an additional
Seekingalpha · 04/09 11:32
DJ Reneo Pharmaceuticals IPO Priced at Low End of Views >RPHM
Dow Jones · 04/09 09:55
Reneo Pharmaceuticals Prices Initial Public Offering of 6.25M Shares at $15.00 Each >RPHM
Reneo Pharmaceuticals Prices Initial Public Offering of 6.25M Shares at $15.00 Each >RPHM
Dow Jones · 04/09 01:46
News On Reneo Pharmaceuticals Inc. (RENP.XX) Now Under RPHM
News On Reneo Pharmaceuticals Inc. (RENP.XX) Now Under RPHM
Dow Jones · 04/08 21:09
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RPHM. Analyze the recent business situations of Reneo Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Chairman/Founder/Executive Director
Mike Grey
President/Chief Executive Officer/Director/Primary Contact
Gregory Flesher
Co-Founder/Director
Niall O'donnell
Chief Operating Officer
Wendy Johnson
Vice President - Operations
Lynn Purkins
Other
Alejandro Dorenbaum
No Data
About RPHM
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the developing therapies for patients with rare genetic mitochondrial diseases. The Company is engaged in developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to transcription of genes involved in mitochondrial function and fatty acid oxidation (FAO). The Company is developing REN001 in the three rare genetic diseases that present with myopathy and have unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). The Company has completed Phase I b clinical trial in patients with PMM to REN001. It is conducting open-label Phase I b clinical trials of REN001 with LC-FAOD and with McArdle disease.

Webull offers kinds of Reneo Pharmaceuticals Inc stock information, including NASDAQ:RPHM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPHM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RPHM stock methods without spending real money on the virtual paper trading platform.